syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
![Syros Pharmaceuticals logo](/files/LOGO/1556263-SYRS.png)
Company profile
Ticker
SYRS
Exchange
Website
CEO
Nancy Simonian
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LS22, Inc.
SEC CIK
Corporate docs
Subsidiaries
Syros Securities Corporation • Syros Pharmaceuticals (Ireland) Limited • Tyme Technologies, Inc. • Tyme, Inc. ...
SYRS stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
6 Jun 24
10-Q
2024 Q1
Quarterly report
14 May 24
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
S-8
Registration of securities for employees
27 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
19 Dec 23
Transcripts
SYRS
Earnings call transcript
2024 Q1
14 May 24
SYRS
Earnings call transcript
2023 Q3
14 Nov 23
SYRS
Earnings call transcript
2023 Q2
8 Aug 23
SYRS
Earnings call transcript
2023 Q2
8 Aug 23
SYRS
Earnings call transcript
2023 Q1
10 May 23
SYRS
Earnings call transcript
2022 Q4
2 Mar 23
SYRS
Earnings call transcript
2022 Q3
14 Nov 22
SYRS
Earnings call transcript
2022 Q2
9 Aug 22
SYRS
Earnings call transcript
2022 Q1
16 May 22
SYRS
Earnings call transcript
2021 Q4
15 Mar 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 85.64 mm | 85.64 mm | 85.64 mm | 85.64 mm | 85.64 mm | 85.64 mm |
Cash burn (monthly) | 18.67 mm | 1.85 mm | 10.31 mm | 10.56 mm | 10.37 mm | 8.66 mm |
Cash used (since last report) | 72.19 mm | 7.16 mm | 39.86 mm | 40.83 mm | 40.08 mm | 33.48 mm |
Cash remaining | 13.46 mm | 78.49 mm | 45.79 mm | 44.81 mm | 45.56 mm | 52.16 mm |
Runway (months of cash) | 0.7 | 42.4 | 4.4 | 4.2 | 4.4 | 6.0 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 80 |
Opened positions | 72 |
Closed positions | 1 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 108.81 bn |
Total shares | 28.44 mm |
Total puts | 500.00 |
Total calls | 29.20 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Bain Capital Life Sciences Investors | 2.75 mm | $14.71 bn |
Artal | 2.51 mm | $13.40 bn |
Samsara BioCapital | 2.49 mm | $14.41 mm |
Bain Capital Life Sciences Fund II | 2.12 mm | $0.00 |
Adage Capital Partners GP, L.L.C. | 2.07 mm | $11.08 bn |
Samsara BioCapital | 1.79 mm | $9.56 bn |
Avidity Partners Management | 1.67 mm | $8.95 bn |
Point72 Asset Management | 1.47 mm | $7.87 bn |
Artal International S.C.A. | 1.46 mm | $0.00 |
Ally Bridge MedAlpha Master Fund | 1.44 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Jun 24 | Young Richard A | Common Stock | Sell | Dispose S | No | Yes | 5.12 | 34,837 | 178.37 k | 8,000 |
5 Jun 24 | Sue Gail Eckhardt | Common Stock | Grant | Acquire A | No | No | 0 | 4,000 | 0.00 | 16,000 |
5 Jun 24 | Sue Gail Eckhardt | Stock Option Common Stock | Grant | Acquire A | No | No | 5.3 | 6,000 | 31.80 k | 6,000 |
5 Jun 24 | Fanucci Marsha | Common Stock | Grant | Acquire A | No | No | 0 | 4,000 | 0.00 | 16,000 |
5 Jun 24 | Fanucci Marsha | Stock Option Common Stock | Grant | Acquire A | No | No | 5.3 | 6,000 | 31.80 k | 6,000 |
5 Jun 24 | Young Richard A | Common Stock | Grant | Acquire A | No | No | 0 | 4,000 | 0.00 | 42,837 |
5 Jun 24 | Young Richard A | Stock Option Common Stock | Grant | Acquire A | No | No | 5.3 | 6,000 | 31.80 k | 6,000 |
5 Jun 24 | Tyson Timothy | Common Stock | Grant | Acquire A | No | No | 0 | 4,000 | 0.00 | 33,189 |
5 Jun 24 | Tyson Timothy | Stock Option Common Stock | Grant | Acquire A | No | No | 5.3 | 6,000 | 31.80 k | 6,000 |
Press releases
Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
24 Jul 24
Alltrna Announces Updates to Its Board of Directors
17 Jul 24
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
18 Jun 24
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
13 Jun 24
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
14 May 24